Categories: Blood diseases, Bone diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Neutropenia

MalaCards integrated aliases for Neutropenia:

Name: Neutropenia 12 29 55 6 44 15 38 72
Leukopenia 72


External Ids:

Disease Ontology 12 DOID:1227
ICD9CM 35 288.0 288.00
MeSH 44 D009503
SNOMED-CT 68 72885007
ICD10 33 D70 D70.9
UMLS 72 C0023530 C0027947

Summaries for Neutropenia

MalaCards based summary : Neutropenia, also known as leukopenia, is related to severe congenital neutropenia autosomal dominant and cyclic neutropenia. An important gene associated with Neutropenia is VPS13B (Vacuolar Protein Sorting 13 Homolog B), and among its related pathways/superpathways are JAK-STAT signaling pathway (KEGG) and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Ceftazidime and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and neutrophil, and related phenotypes are no effect and hematopoietic system

Wikipedia : 75 Neutropenia is an abnormally low concentration of neutrophils (a type of white blood cell) in the blood.... more...

Related Diseases for Neutropenia

Diseases in the Neutropenia family:

Neutropenia, Chronic Familial Neutropenia, Severe Congenital, 1, Autosomal Dominant
Neutropenia, Severe Congenital, 3, Autosomal Recessive Neutropenia, Severe Congenital, 4, Autosomal Recessive
Neutropenia, Severe Congenital, 2, Autosomal Dominant Neutropenia, Severe Congenital, 5, Autosomal Recessive
Neutropenia, Severe Congenital, 6, Autosomal Recessive Neutropenia, Severe Congenital, 7, Autosomal Recessive
Severe Congenital Neutropenia Severe Congenital Neutropenia Autosomal Dominant
Acquired Neutropenia Autosomal Recessive Severe Congenital Neutropenia

Diseases related to Neutropenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 944)
# Related Disease Score Top Affiliating Genes
1 severe congenital neutropenia autosomal dominant 34.5 GFI1 ELANE
2 cyclic neutropenia 34.3 IL3 G6PC3 ELANE CSF3 CSF2
3 felty syndrome 33.6 IL3 CSF3 CSF2
4 severe congenital neutropenia 32.8 WAS VPS45 JAGN1 IL3 HAX1 GFI1
5 bacterial infectious disease 31.6 ELANE CSF3 CSF2
6 granulocytopenia 31.6 IL3 CSF3 CSF2
7 leukemia, acute myeloid 31.0 IL3 GFI1 CSF3R CSF3 CSF2
8 aplastic anemia 30.7 IL3 CSF3R CSF3 CSF2
9 myelodysplastic syndrome 30.5 TOP1 IL3 CSF3R CSF3 CSF2
10 dyskeratosis congenita 30.3 USB1 CSF3 CSF2
11 acute promyelocytic leukemia 30.1 IL3 ELANE CSF3R CSF3
12 irinotecan toxicity 30.1 UGT1A1 TOP1
13 chronic myelomonocytic leukemia 30.0 TOP1 CSF3R CSF2
14 leukemia, chronic myeloid 30.0 IL3 CSF3R CSF3 CSF2 CD177
15 trichosporonosis 30.0 CSF3 CSF2
16 anemia of prematurity 29.9 IL3 CSF3 CSF2
17 chronic neutrophilic leukemia 29.8 CSF3R CSF3
18 capillary leak syndrome 29.8 ELANE CSF2
19 pancytopenia 29.7 TPMT IL3 CSF3 CSF2
20 hematologic cancer 29.5 TOP1 IL3 CSF3R CSF3 CSF2
21 poikiloderma with neutropenia 12.8
22 neutropenia, severe congenital, 3, autosomal recessive 12.7
23 3-methylglutaconic aciduria with cataracts, neurologic involvement, and neutropenia 12.7
24 neutropenia, nonimmune chronic idiopathic, of adults 12.6
25 neutropenia, severe congenital, x-linked 12.6
26 neutropenia, severe congenital, 5, autosomal recessive 12.6
27 neutropenia, severe congenital, 4, autosomal recessive 12.6
28 idiopathic neutropenia 12.6
29 neutropenia, severe congenital, 1, autosomal dominant 12.6
30 neutropenia, severe congenital, 7, autosomal recessive 12.6
31 neutropenia, severe congenital, 2, autosomal dominant 12.6
32 neutropenia, severe congenital, 6, autosomal recessive 12.5
33 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 12.5
34 transient neonatal neutropenia 12.4
35 neutropenia, chronic familial 12.3
36 neonatal alloimmune neutropenia 12.3
37 barth syndrome 12.3
38 neutropenia, lethal congenital, with eosinophilia 12.3
39 acquired neutropenia 12.3
40 autosomal recessive severe congenital neutropenia 12.2
41 onychotrichodysplasia and neutropenia 12.2
42 elane-related neutropenia 12.2
43 constitutional neutropenia 12.2
44 clpb deficiency 12.1
45 neutropenia-monocytopenia-deafness syndrome 12.1
46 obsolete: susceptibility to neutropenia due to mercaptopurine treatment 12.1
47 obsolete: susceptibility to neutropenia due to azathioprine treatment 12.1
48 constitutional neutropenia with extra-hematopoietic manifestations 12.1
49 autosomal recessive severe congenital neutropenia due to cxcr2 deficiency 12.1
50 immunodeficiency 55 12.0

Comorbidity relations with Neutropenia via Phenotypic Disease Network (PDN): (show all 44)

Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Leukemia Agammaglobulinemia, X-Linked
Anemia, Autoimmune Hemolytic Bladder Cancer
Bronchitis Colorectal Cancer
Decubitus Ulcer Deficiency Anemia
Esophageal Cancer Esophageal Candidiasis
Esophagitis Felty Syndrome
Female Breast Cancer Gastric Cancer
Heart Disease Hepatic Encephalopathy
Hydronephrosis Hypersplenism
Hypothyroidism Immune Deficiency Disease
Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1 Intestinal Obstruction
Iron Deficiency Anemia Leukemia, Chronic Lymphocytic
Main Bronchus Cancer Megakaryocytic Leukemia
Oral Candidiasis Ovarian Cancer
Paralytic Ileus Pneumocystosis
Portal Hypertension Postinflammatory Pulmonary Fibrosis
Primary Thrombocytopenia Protein-Energy Malnutrition
Pulmonary Fibrosis and/or Bone Marrow Failure, Telomere-Related, 2 Respiratory Failure
Retinitis Pigmentosa and Erythrocytic Microcytosis Rheumatoid Arthritis
Sideroblastic Anemia Systemic Lupus Erythematosus

Graphical network of the top 20 diseases related to Neutropenia:

Diseases related to Neutropenia

Symptoms & Phenotypes for Neutropenia

GenomeRNAi Phenotypes related to Neutropenia according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 CD177 CLPB CSF2 CSF3 CSF3R ELANE

MGI Mouse Phenotypes related to Neutropenia:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 CD177 CSF2 CSF3 CSF3R ELANE G6PC3
2 immune system MP:0005387 9.36 CD177 CSF2 CSF3 CSF3R ELANE G6PC3

Drugs & Therapeutics for Neutropenia

DrugBank drugs 16 :

# Drug Name Indication DrugBank ID
1 Filgrastim This drug is a leucocyte growth factor [FDA label] indicated to: Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [FDA label]. Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment in patients with acute myeloid leukemia (AML) [FDA label] Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) [FDA label] Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis [FDA label] Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia [FDA label]. Neupogen is approved for treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident [L3739]. DB00099
2 Lipegfilgrastim Indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) [L2441]. DB13200
3 Pegfilgrastim Pegfilgrastim is indicated for use in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies to reduce the incidence of infection. It is also indicated to increase in patients with acute myelosuppresive radiation exposure. DB00019
4 Sargramostim For the treatment of cancer and bone marrow transplant DB00020

Drugs for Neutropenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 667)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Lumefantrine Approved Phase 4 82186-77-4 6437380
Artemether Approved Phase 4 71963-77-4 68911 119380
Teicoplanin Approved, Investigational Phase 4 61036-62-2
Azathioprine Approved Phase 4 446-86-6 2265
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
Sodium citrate Approved, Investigational Phase 4 68-04-2
acetic acid Approved Phase 4 64-19-7 176
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
Doripenem Approved, Investigational Phase 4 148016-81-3 73303
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Promethazine Approved, Investigational Phase 4 60-87-7 4927
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
Chlorpheniramine Approved Phase 4 132-22-9, 113-92-8 2725
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
Ranitidine Approved Phase 4 66357-35-5, 66357-59-3 3001055
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Polyestradiol phosphate Approved Phase 4 28014-46-2
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
Sucralfate Approved Phase 4 54182-58-0
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
29 Brodalumab Approved, Investigational Phase 4 1174395-19-7
Acetaminophen Approved Phase 4 103-90-2 1983
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
Cefpirome Approved Phase 4 84957-29-9 5479539
Tazobactam Approved Phase 4 89786-04-9 123630
Piperacillin Approved Phase 4 66258-76-2 43672
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
Aztreonam Approved Phase 4 78110-38-0 5742832 5362041
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 64778 441130
Cilastatin Approved, Investigational Phase 4 82009-34-5 5280454 6435415
Nicotine Approved Phase 4 54-11-5 942 89594
Radium Ra 223 dichloride Approved, Investigational Phase 4 444811-40-9
Abatacept Approved Phase 4 332348-12-6 10237
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
Hydroxyurea Approved Phase 4 127-07-1 3657
Ofloxacin Approved Phase 4 82419-36-1 4583
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
50 Daratumumab Approved Phase 4 945721-28-8

Interventional clinical trials:

(show top 50) (show all 1052)
# Name Status NCT ID Phase Drugs
1 Optimal Timing and Duration of Daily G-CSF With Adjuvant TAC Chemotherapy in Node-positive Breast Cancer;Multicenter, Randomized, Open Label, Clinically IV Phase Unknown status NCT01571518 Phase 4 late leukostim;early leukostim
2 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
3 Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric & Adolescent Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT01135589 Phase 4 Micafungin
4 A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer Unknown status NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
5 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
6 G-CSF (Filgrastim) or Pegfilgrastim Secondary Prophylaxis In The Adjuvant Chemotherapy Of Early Breast Cancer Unknown status NCT00030758 Phase 4
7 Prospective Unblinded Randomized Trial to Examine Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia Unknown status NCT02463747 Phase 4 Piperacillin/tazobactam;Ceftazidim;Meropenem;Vancomycin
8 Validation of Central Venous (Port A Cath®) Blood Draws for Ciprofloxacin Pharmacokinetic Research in Patients Under Treatment for Childhood Cancer Unknown status NCT02967341 Phase 4
9 Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis. Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
10 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
11 Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau. Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
12 Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients Completed NCT00454272 Phase 4 Teicoplanin;Vancomycin
13 Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia Following Administration by 4-hour Infusion and Bolus Injection. Completed NCT02213783 Phase 4 Imipenem;Imipenem
14 A Randomized, Open Label, Multicenter Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
15 A Multicenter, Open-label, Phase 4 Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy Completed NCT00125723 Phase 4
16 A Multi-center, Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805205 Phase 4 PEG-rhG-CSF
17 Randomized Open Label Clinical Trial Directed to Optimize the Duration of Empirical Antimicrobial Therapy in Haematologic Patients With Febrile Neutropenia Completed NCT01581333 Phase 4 Empirical antimicrobial treatment discontinuation;Standard empirical antimicrobial treatment discontinuation
18 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
19 A Phase IV Clinical Trial of Patients With Solid Tumours Receiving Granocyte 34 (Granulocyte Colony Stimulating Factor (G-CSF)) as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Taxotere (Docetaxel) Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
20 A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context. Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
21 Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induces Febrile Neutropenia Completed NCT02173262 Phase 4 G-CSF;Ciprofloxacin
22 Tobramycin én Gang Daglig Mot Tre Ganger Daglig, Gitt Med Benzylpenicillin, Til Pasienter Med nøytropen Feber Completed NCT00257790 Phase 4 Tobramycin once a day
23 Citrate- Versus Acetate-Based Dialysate in Bicarbonate Haemodialysis: Consequences on Haemodynamics, Coagulation, Acid-Base Status and Electrolytes Completed NCT00718289 Phase 4
24 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
25 Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients With Possible Bacterial Infection Completed NCT01401010 Phase 4 Doripenem;doripenem
26 ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment. Completed NCT00386802 Phase 4 Antifungal drug. VORICONAZOL. (VFEND®)
27 Pharmacokinetics of Mycophenolate Mofetil Alone and in Combination With Valganciclovir in Renal and Heart Transplant Recipients Completed NCT00189150 Phase 4 Mycophenolate mofetil;Valganciclovir
28 The Multi-center, Open-label,Randomized Comparison Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805153 Phase 4 PEG-rhG-CSF;rhG-CSF
29 Health Economic Evaluation of Rapid Detection of Bacteraemia and Fungemia by Real Time PCR for Cases of Febrile Neutropenia, Suspicion of Endocarditis and Severe Sepsis in Intensive Care Units Completed NCT00709358 Phase 4
30 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
31 Evaluate the Safety of Combination of Orectalip® (Oxaliplatin), Fluorouracil and Leucovorin as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
32 Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana Completed NCT01086878 Phase 4 cotrimoxazole
33 A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection Completed NCT00686543 Phase 4 Posaconazole
34 Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients Completed NCT01114165 Phase 4
35 Effect of Granulocyte-macrophage Stimulating Factor on Prevention and Treatment of Invasive Fungal Diseases in the Recipients of Allogeneic Stem Cell Transplantation: A Prospective Multicenter Randomized Phase 4 Trial Completed NCT01232504 Phase 4 rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
36 PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
37 Comparison of a Tacrolimus/Sirolimus/Prednisone Regimen Versus Tacrolimus/Azathioprine/Prednisone Immunosuppressive Regimen in Lung Transplantation Completed NCT00321906 Phase 4 azathioprine;sirolimus
38 Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
39 Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
40 Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients Completed NCT00969462 Phase 4 Doxorubicin
41 Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
42 Steady-State Comparative Bioavailability Study in Patients Requiring Anti-Fungal Prophylaxis Comparing Twice a Day Dosing of Lozanoc® (Mayne) Regardless of Food With Sporanox® (Janssen) Under Fed Conditions Completed NCT02621905 Phase 4 Sporanox;Lozanoc
43 A Ramdomized Double Blined Placebo Controlled Oral Zinc Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Stem Cell Support Completed NCT00449592 Phase 4 Zinc;Placebo
44 A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia: a Randomized Prospective Study Completed NCT00702871 Phase 4 Ranitidine;Sucralfate
45 Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection Completed NCT01198236 Phase 4 Itraconazole
46 Low Dose Peginterferon and Ribavirin Therapy for Patients With Chronic Hepatitis C Infected With Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin
47 Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins in Patients With Presumptive Candidemia Completed NCT00839540 Phase 4 micafungin;Micafungin;Caspofungin
48 A Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies Completed NCT03403036 Phase 4 Brodalumab
49 Phase 4 Randomized, Controlled Study Comparing Sirolimus and Mycophenolate Mofetil to Prevent or Reverse Progression in Pediatric Renal Transplants With Chronic Allograft Nephropathy Completed NCT00188955 Phase 4 sirolimus
50 Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation Completed NCT00331162 Phase 4 Alemtuzumab;Anti-Thymocyte Globulin

Search NIH Clinical Center for Neutropenia

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Immunoglobulins, Intravenous

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Neutropenia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: neutropenia

Genetic Tests for Neutropenia

Genetic tests related to Neutropenia:

# Genetic test Affiliating Genes
1 Neutropenia 29

Anatomical Context for Neutropenia

MalaCards organs/tissues related to Neutropenia:

Lung, Breast, Neutrophil, Bone, Myeloid, Bone Marrow, Prostate

Publications for Neutropenia

Articles related to Neutropenia:

(show top 50) (show all 39512)
# Title Authors PMID Year
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents. 9 38
20175767 2010
Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. 9 38
20066544 2010
Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea & Westminster TEN management protocol [corrected]. 9 38
19912214 2010
Circadian rhythm of neutrophil counts and granulocyte macrophage-colony stimulating factor (GM-CSF) under clozapine treatment: a case report. 9 38
19396726 2010
Genetic insights into congenital neutropenia. 9 38
19440858 2010
Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer. 9 38
19786849 2010
Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? 9 38
20136357 2010
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. 9 38
20068078 2010
Which role for rituximab in hairy cell leukemia? Reflections on six cases. 9 38
20051682 2010
Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. 9 38
20021291 2010
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. 9 38
19297346 2010
Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1. 9 38
19608554 2009
Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more. 9 38
19699815 2009
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. 9 38
19556318 2009
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence. 9 38
19916175 2009
An outbreak of Crimean-Congo hemorrhagic fever in western Anatolia, Turkey. 9 38
19409826 2009
Prospective study of Chikungunya virus acute infection in the Island of La Réunion during the 2005-2006 outbreak. 9 38
19893613 2009
Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. 9 38
19696793 2009
G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. 9 38
19794089 2009
SBDS expression and localization at the mitotic spindle in human myeloid progenitors. 9 38
19759903 2009
A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. 9 38
19770418 2009
Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. 9 38
19756005 2009
Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. 9 38
19223932 2009
Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma. 9 38
19446318 2009
A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. 9 38
19457938 2009
Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. 9 38
19682195 2009
Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. 9 38
19513514 2009
[Allelic variants of TPMT and the risk of leucopenia and neutropenia in patients treated for acute leukaemia]. 9 38
20081263 2009
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. 9 38
19604089 2009
[Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI]. 9 38
19620808 2009
Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. 9 38
19435433 2009
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. 9 38
19707503 2009
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. 9 38
19438482 2009
Complement factors C3a and C5a have distinct hemodynamic effects in the rat. 9 38
19285573 2009
Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients. 9 38
19200137 2009
XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. 9 38
19404210 2009
A novel mutation in the G4.5 (TAZ) gene in a Greek patient with Barth syndrome. 9 38
19261493 2009
UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. 9 38
19450125 2009
Neutropenia in congenital nephrotic syndrome of the Finnish type: role of urinary ceruloplasmin loss. 9 38
19423745 2009
Ela2 mutations and clinical manifestations in familial congenital neutropenia. 9 38
19415009 2009
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases. 9 38
19151787 2009
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. 9 38
19390945 2009
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). 9 38
19242368 2009
Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome. 9 38
19454236 2009
Shwachman-Diamond syndrome neutrophils have altered chemoattractant-induced F-actin polymerization and polarization characteristics. 9 38
19211642 2009
[Autoimmune thrombocytopenia, neutropenia and hemolysis]. 9 38
19225748 2009
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. 9 38
19347726 2009
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. 9 38
18685564 2009
Mitochondrial defects lie at the basis of neutropenia in Barth syndrome. 9 38
19057200 2009
Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. 9 38
19147084 2009

Variations for Neutropenia

ClinVar genetic disease variations for Neutropenia:

# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 VPS13B NM_017890.4(VPS13B): c.4620del (p.Ser1541fs) deletion Pathogenic rs1057518939 8:100523652-100523652 8:99511424-99511424
2 subset of 47 genes:TBX1 GRCh37/hg19 22q11.21(chr22: 18894835-21505417) copy number loss Pathogenic 22:18894835-21505417 :0-0
3 VPS13B NM_017890.4(VPS13B): c.11314C> T (p.Gln3772Ter) single nucleotide variant Pathogenic/Likely pathogenic rs386834061 8:100880540-100880540 8:99868312-99868312
4 SLC37A4 NM_001164277.1(SLC37A4): c.81T> A (p.Asn27Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs193302889 11:118899999-118899999 11:119029289-119029289
5 46;XY;t(16;20)(q23.1;p11.22) Translocation Uncertain significance
6 46;XX;inv(2)(q13q14.2) inversion Uncertain significance
7 XDH NM_000379.4(XDH): c.3647C> A (p.Pro1216His) single nucleotide variant Uncertain significance rs143981573 2:31562482-31562482 2:31339616-31339616
8 XDH NM_000379.4(XDH): c.1172C> T (p.Pro391Leu) single nucleotide variant Uncertain significance 2:31602803-31602803 2:31379937-31379937

Expression for Neutropenia

Search GEO for disease gene expression data for Neutropenia.

Pathways for Neutropenia

GO Terms for Neutropenia

Biological processes related to Neutropenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.67 IL3 CSF3R CSF3 CSF2
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.5 IL3 HAX1 CSF3
3 drug metabolic process GO:0017144 9.43 UGT1A1 TPMT
4 positive regulation of actin cytoskeleton reorganization GO:2000251 9.4 HAX1 CSF3
5 regulation of myeloid cell differentiation GO:0045637 9.26 CSF3R CSF2
6 neutrophil migration GO:1990266 9.16 JAGN1 CD177
7 glucose-6-phosphate transport GO:0015760 8.96 SLC37A4 G6PC3
8 neutrophil differentiation GO:0030223 8.62 JAGN1 CSF2

Sources for Neutropenia

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed